Journal: bioRxiv

Article Title: CD47 as a potential biomarker for the early diagnosis of severe COVID-19

doi: 10.1101/2021.03.01.433404

Figure Lengend Snippet: SARS-CoV-2 infection is associated with increased CD47 levels. A) TF protein abundance in uninfected (control) and SARS-CoV-2-infected (virus) Caco-2 cells (data derived from . P-values were determined by two-sided Student’s t-test. B) CD47 and SARS-CoV-2 N protein levels and virus titres (genomic RNA determined by PCR) in SARS-CoV-2 strain FFM7 (MOI 1)-infected air-liquid interface cultures of primary human bronchial epithelial (HBE) cells and SARS-CoV-2 strain FFM7 (MOI 0.1)-infected Calu-3 cells. Uncropped blots are provided in Suppl. Figure 1. C) CD47 mRNA levels in post mortem samples from COVID-19 patients (data derived from ). P-values were determined by two-sided Student’s t-test.

Article Snippet: Detection occurred by using specific antibodies against CD47 (1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinityTM, # 130-101-343, Miltenyi Biotec), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological), and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen).

Techniques: Infection, Quantitative Proteomics, Control, Virus, Derivative Assay

Journal: bioRxiv

Article Title: CD47 as a potential biomarker for the early diagnosis of severe COVID-19

doi: 10.1101/2021.03.01.433404

Figure Lengend Snippet: Results of the PubMed ( https://pubmed.ncbi.nlm.nih.gov ) literature search for “CD47 aging” (A) and “CD47 hypertension” (B). C) Overview figure of the data derived from the literature searches. Age-related increased CD47 levels may contribute to pathogenic conditions associated with severe COVID-19.

Article Snippet: Detection occurred by using specific antibodies against CD47 (1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinityTM, # 130-101-343, Miltenyi Biotec), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological), and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen).

Techniques: Derivative Assay

Journal: bioRxiv

Article Title: CD47 as a potential biomarker for the early diagnosis of severe COVID-19

doi: 10.1101/2021.03.01.433404

Figure Lengend Snippet: Results of the PubMed ( https://pubmed.ncbi.nlm.nih.gov ) literature search for “CD47 diabetes” (A). B) Overview figure of the data derived from the literature search. Hyperglycaemia- and diabetes-induced increased CD47 levels may contribute to immune escape of SARS-CoV-2-infected cells.

Article Snippet: Detection occurred by using specific antibodies against CD47 (1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinityTM, # 130-101-343, Miltenyi Biotec), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological), and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen).

Techniques: Derivative Assay, Infection

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Immunohistochemistry, Staining, Immunohistochemical staining

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Patient characteristics by pre-NACT CD47 expression

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques:

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Immunohistochemistry

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Wilcoxon signed ranks test of the CD47 expression pre- and post-NACT

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Multivariate prognostic analysis

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Control

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Fluorescence

Journal: Frontiers in Immunology

Article Title: IL-27 Derived From Macrophages Facilitates IL-15 Production and T Cell Maintenance Following Allergic Hypersensitivity Responses

doi: 10.3389/fimmu.2021.713304

Figure Lengend Snippet: CD3, CD47, and CD172a expression in human ACD clusters. (A–C) Immunofluorescence staining of CD3 (green), CD47 (red), CD172a (purple), CD14 [green, a serial slide section with the staining of CD172a (purple)], and Hoechst (blue) in human donor-matched patch-test negative control and patch-test (+) ACD skin. White dashed lines mark the epidermal-dermal junction. Data are representative of 3 patient samples per tested condition. (A) Scale bars are 200 µm (left) and 100 µm (right). (B, C) Scale bars are 20 µm.

Article Snippet: Mouse IgG1 isotype control (MOPC-21) (Tonbo Biosciences), Goat IgG isotype control (R&D Systems), Sheep IgG isotype control (R&D Systems), Rabbit isotype control (Southern Biotech, Birmingham, AL), anti-human CD14 (61D3, Tonbo Biosciences), anti-human iNOS (polyclonal, Thermo Fisher Scientific), anti-human CD8 (MCD8, Santa Cruz Biotechnology, Dallas, TX), and IL27R (polyclonal, R&D Systems), anti-human IL-27 (polyclonal, R&D Systems), anti-human CD86 (IT2.2, Biolegend), anti-human CD3 (SP7, Abcam, Cambridge, England), anti-human CD47 (polyclonal, R&D Systems), anti-human SIRP alpha (CD172a) (OTI7B3, Origene), anti-human IL-15 (polyclonal, R&D systems), anti-human BCL2 (clone 100, BioLegend), anti-mouse CD3 (17A2, Tonbo Biosciences), and anti-mouse CD8 (YTS 105.18, Novus Biologicals, Littleton, CO) followed by reaction with Cy3, Alexa Fluor 555, Alexa Fluor 647, Alexa Fluor 488, or FITC-conjugated secondary antibodies (Thermo Fisher Scientific).

Techniques: Expressing, Immunofluorescence, Staining, Negative Control

Journal: Journal of nanobiotechnology

Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.

doi: 10.1186/s12951-023-02206-5

Figure Lengend Snippet: Fig. 1 A Schematic representation of the preparation of rtPA-loaded CSM derived from platelets. B Representative mean hydrodynamic diameter of CSM and CSM@rtPA before and after lyophilization (CSM@rtPA/L) process measured by DLS. Data represent mean ± SEM (n = 3, independent samples). C Representative mean diameter of CSM and CSM@rtPA before and after lyophilization process (CSM@rtPA/L) measured by NTA. Data represent mean ± SEM (n = 3, independent samples). D Representative STEM-in SEM images of CSM@rtPA negatively stained with uranyl acetate. Scale bars: 200 nm. E Loading capacity of rtPA encapsulated in CSM samples. Data represent mean ± SEM (n = 3, independent samples). F Representative density plots and quantitative analysis of CSM and CSM@rtPA measured by FC. Scatter density plots of Green fluorescence signal (Green-B channel, rtPA channel) versus Red fluorescence signal (Red-R channel, CellMask DeepRed channel) for CSM, CSM@rtPA, and CSM@rtPA sample after labeling with CellMask Deep Red for lipid staining. Mean fluorescence intensities (MFI) for Green-B channel (D) and Red-R channel. Data represent mean ± SEM (n = 3, independent samples). G. Schematic representation of platelets and platelet-derived CSM surface proteins studied by APC-fluorescently labeled antibodies: anti-hCD47 Ab and anti-hCD42b/GPlba Ab. In vitro Ab binding to platelets and CSM@rtPA before and after lyophilization process. Representative MFI histogram of Red-R channel (APC signal) for platelets, CSM@rtPA and CSM@rtPA/L samples after incubation with APC-anti-CD47 and APC-anti-CD42b/GPIbα antibodies

Article Snippet: Then, fluorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /106 cells) and the samples were analyzed by flow cytometer.

Techniques: Derivative Assay, Lyophilization, Staining, Fluorescence, Labeling, In Vitro, Binding Assay, Incubation

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: Preparation and characterization of anti‐CD47‐PCM@NP. A) Hydrodynamic size and zeta potential of CM vesicles, PLGA cores (NP), PCM@NP, and anti‐CD47‐PCM@NP. Data are means ± SD ( n = 3). B) Colocalization of NP/C6 (green) with DiD‐PCM (red), and the colocalization of FITC‐antibody (green) with DiD‐PCM@NP (red), both assessed by confocal laser scanning microscope (CLSM) (scale bar = 5 µm). C) Transmission electron micrographs of (a) NP, (b) CM vesicle, (c) PCM@NP, (d) Anti‐CD47‐PCM@NP, and (e) multiple anti‐CD47‐PCM@NP. All scale bars = 100 nm. D) SDS‐PAGE protein analysis of NP, PCM@NP, CM vesicles, and cancer cell lysate. Samples were tested at equal protein concentrations. CD47 protein and membrane‐specific protein on the cancer cell membrane were efficiently retained on the extracted membrane vesicles and the PCM@NP, detected by western blot. E) Determination of the antibody labeled by PE loaded on the surface of anti‐CD47‐PCM@NP by flow nanoanalyzer. F) The binding affinity of the antibody to the CM vesicles by surface plasmon resonance (SPR).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: Zeta Potential Analyzer, Laser-Scanning Microscopy, Transmission Assay, SDS Page, Membrane, Western Blot, Labeling, Binding Assay, SPR Assay

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: Anti‐CD47‐PCM@NP effectively distinguished target cells from CD47‐expressing nontarget cells in vitro through indirect active targeting. A) Anti‐CD47‐PCM@NP avoided the blocking of CD47 on RBC and subsequent phagocytosis thus circumvented the on‐target toxicity of free anti‐CD47 towards RBC through the INTACT strategy. Scale bar = 50 µm. B,C) PCM@NP and anti‐CD47‐PCM@NP efficiently escaped the capture by B) macrophages with enhanced and parallel cellular uptake by C) target 4T1 cells, measured by flow cytometry. The antibody selectively dissociated from the carrier PCM@NP at the presence of 4T1 cells with high expression of D) CD47 in contrast to E) CD47 −/− 4T1 cells, shown by colocalization images and distribution map of PE‐antibody (red) and PCM@NP/C6 (green). Scale bar = 20 µm (multi‐cell images), 2 µm (single‐cell images). F) The schematic diagram of the microfluidic device. The tumor cells were cultured in the cavity of the microfluidic chip till adherence, and then exposed to flowing anti‐CD47 or anti‐CD47‐PCM@NP, and fluorescent images were captured at predetermined time points. G) Free anti‐CD47 sufficiently bound to the surface of 4T1 cells with high expression of CD47 (a). The antibody dissociated from PCM@NP at the presence of 4T1 cells (b), in contrast with CD47 −/− 4T1 group (c) (antibody labeled with FITC, green. PCM@NP labeled with DiD, red). Scale bar = 10 µm. Original movies are shown in Movie S1 (Supporting Information) (a), Movie S2 (Supporting Information) (b), and Movie S3 (Supporting Information) (c), respectively. Data are presented as mean ± SD ( n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS represents non‐significance).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: Expressing, In Vitro, Blocking Assay, Flow Cytometry, Cell Culture, Labeling

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: Evaluation of the biological functions of anti‐CD47‐PCM@NP in vivo. A) In vivo and ex vivo targeting ability of anti‐CD47‐PCM@NP and anti‐CD47 in tumor‐bearing mice models determined by live imaging. B) The semiquantitative analysis of the ratio of fluorescence intensity (tumor/liver) of ex vivo imaging. C) In vivo biodistribution of coumarin 6 (C6)‐labeled formulations in tumor‐bearing mice models at (a) 2 h, (b) 4 h, (c) 8 h, and (d) 12 h after i.v. injection of NP/C6, PCM@NP/C6 and anti‐CD47‐PCM@NP/C6. Data are presented as mean ± SD ( n = 3) (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS represents non‐significance).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: In Vivo, Ex Vivo, Imaging, Fluorescence, Labeling, Injection

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: Antitumor efficacy of anti‐CD47‐PCM@NP and mechanistic investigation by CyTOF analysis. A) Representative images and phagocytic index of C57BL/6 bone marrow‐derived macrophages (BMDM) phagocytosing tumor cells following treatment with PCM@NP, anti‐CD47, and anti‐CD47‐PCM@NP. Scale bar = 50 µm. B) Timeline of the anti‐tumor efficacy study on tumor‐bearing mice (red arrows indicate intravenous administrations), and average tumor growth curves and picture of tumor tissues after the treatment. C) Individual tumor growth curves in each group. D) viSNE plot of intratumoral cells in tumor tissues after treatment with saline, PCM@NP, anti‐CD47, anti‐CD47‐PCM@NP and all groups merged. E) Heat map of the surface molecule and functional molecule expression of different subsets of immune cells in tumor tissues from all groups merged. F) tSNE visualization of all samples with the expression of CD4 and CD8a respectively. G) Percentage of cells in each cluster after treatment from each group. Data represented as mean ± SD ( n = 6). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS represents nonsignificance).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: Derivative Assay, Saline, Functional Assay, Expressing

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: The INTACT strategy efficiently delivers antibodies to tumors with reduced in vivo toxicity. A) Anti‐CD47‐PCM@NP exhibited no significant influence on red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and platelet (PLT). Data represented as mean ± SD ( n = 3). B–D) Anti‐CD47‐PCM@NP relieved the occurrence of fungal infection during antitumor treatment. B) Experimental timeline and treatments in tumor‐bearing mice (arrows indicate intravenous administrations). At day 14, mice were infected with C. albicans via tail vein injection. C) Colony‐forming units (CFU) on day 7 in the kidneys of infected mouse models ( n = 6). D) The survival rates of infected mice with different treatments ( n = 12). Data represented as mean ± SD. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS represents non‐significance).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: In Vivo, Infection, Injection

Journal: Advanced Science

Article Title: Overcoming the On‐Target Toxicity in Antibody‐Mediated Therapies via an Indirect Active Targeting Strategy

doi: 10.1002/advs.202206912

Figure Lengend Snippet: The INTACT strategy is adaptive to multiple antibody‐based systems. A) Relative tumor volume growth with anti‐CD47‐PCM@NP/PTX treatment ( n = 6). B–G) The INTACT therapy refined the targeting precision of ADC. B) The diagram of ADC construction: Anti‐CD47 was modified with streptavidin and conjugated with DM1 via the crosslinker BMCC‐biotin. C) The conjugation of ADC was confirmed with SDS‐PAGE. D) Experimental timeline for the anti‐tumor efficacy study and hematology assessments of ADC‐PCM@NP (red arrows indicate intravenous administrations). E) Average tumor growth curves, and picture of the tumor tissues after the treatment ( n = 6). F) Individual tumor growth curves in each group ( n = 6). G) Hematology assessments of red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), and platelet (PLT) ( n = 3). Data represented as mean ± SD. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS represents non‐significance).

Article Snippet: The cells were diluted at 1× 10 6 cells per mL in a culture medium and incubated with 1.0 mg mL −1 of a PE anti‐human/mouse/rat CD47 antibody (E‐AB‐F1016D, Elabscience) or anti‐Neu/ErbB2/HER2 Antibody (SC‐7301, Santa Cruz Biotechnology) and CoraLite488‐conjugated Affinipure coat anti‐mouse IgG(H+L) (SA00013‐1, Proteintech) for 30 min at 4 °C.

Techniques: Modification, Conjugation Assay, SDS Page

Journal: Oncology Letters

Article Title: CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma

doi: 10.3892/ol.2018.8520

Figure Lengend Snippet: Expression of CD47 in oral squamous cell carcinoma cell lines and normal oral keratinocytes, as assessed by immunofluorescence. CD47 was expressed in (A1) Tca8113, (B1) Cal-27 and (C1) SCC-9 cells. (D1) Weak positive staining was observed in normal oral keratinocytes. No expression of CD47 was observed in the control cells (A2-D2; magnification, ×400). CD47, cluster of differentiation 47.

Article Snippet: Subsequently, fixed cells were incubated with 5% normal goat serum (Zhongshan Golden Bridge Ltd.) for 30 min at 37°C and mouse CD47 antibody (1:100; cat. no. FAB4670G; R&D Systems, Inc.) was added overnight at 4°C.

Techniques: Expressing, Immunofluorescence, Staining, Control

Journal: Oncology Letters

Article Title: CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma

doi: 10.3892/ol.2018.8520

Figure Lengend Snippet: Effect of CD47 antibody on the proliferation of Cal-27 cells. The proliferation of Cal-27 cells was inhibited by 5 and 10 µg/ml CD47 antibody. *P<0.05, **P<0.01 and ***P<0.001 vs. control group. CD47, cluster of differentiation 47; OD, absorbance; CCK-8, Cell Counting kit-8.

Article Snippet: Subsequently, fixed cells were incubated with 5% normal goat serum (Zhongshan Golden Bridge Ltd.) for 30 min at 37°C and mouse CD47 antibody (1:100; cat. no. FAB4670G; R&D Systems, Inc.) was added overnight at 4°C.

Techniques: Control, CCK-8 Assay, Cell Counting